Studying why some people with atopic dermatitis have more severe disease
Studies people with atopic dermatitis who carry the IL-4Ra R576 gene variant.
Plain-language title generated from the registry record
Registry title: Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism
Key facts
- Where
- Boston, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 65 years old?
Source: NCT04455906, who can take part
Where in United States
- Boston Children's HospitalBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Boston Children's Hospital
- Trial code
- NCT04455906
- Record updated
- 18 May 2026
- Original description
This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.Read full original descriptionShow less
Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism
This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.
Inclusion: Male or female participants ≥6 to 65 yrs of age; Meet AD Standard Diagnostic Criteria.
Exclusion: Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, JAK inhibitors, azathioprine, methotrexate); Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks; Use of topical steroids, topical calcineurin inhibitors or crisaborale within 7 days; Asthmatics receiving more than 500 μg per day of inhaled corticosteroids; Hypersensitivity to an agent used for the skin decolonization protocol; History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy; Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune disease; Febrile illness at time of visits; Suspected immune deficiency or family history of primary immunodeficiency; Enrollment in another clinical trial; Phototherapy for AD within 4 weeks; Bleach baths within 7 days of the first Visit; Use of oral or topical antibiotics within 21 days of the beginning of the study; Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell lymphoma,,.